Tumor regression by anti-CD40 and interleukin-2: Role of CD40 in hematopoietic cells and organ-specific effects

Lisbeth A. Welniak, Lynnette Shorts, Jeff Subleski, Bruce R. Blazar, Robert H. Wiltrout, William J Murphy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

CD40 stimulation can synergize with interleukin (IL)-2 for antitumor responses against mouse metastatic renal cell carcinomas, with coincident increases in tumor-specific CD8+ T-cell responses and dendritic cell numbers in both the spleen and liver. Because CD40 is present on various hematopoietic-derived cells, endothelial cells, and some tumors themselves, this study was performed to determine whether the antitumor effects of CD40 stimulation and IL-2 were primarily mediated by CD40+ hematopoietic-derived cells. Bone marrow chimeras were created by reconstituting lethally irradiated CD40+/+ recipients with bone marrow from CD40-/- or CD40+/+ mice. Chimeric mice were then implanted orthotopically with renal cancer cells, followed by treatment with anti-CD40 agonist monoclonal antibodies and IL-2. Immune parameters of the spleen and liver were assessed after therapy and correlated with antitumor responses. The antitumor effects in the CD40-/- bone marrow transplantation chimeras were almost completely abrogated after treatment, and this shows that hematopoietically derived CD40+ cells are the principal targets for CD40 stimulation in this model. Although both spleen and liver showed reductions in CD8+ T-cell and dendritic cell expansion in the CD40-/- versus CD40+/+ chimeras after therapy, only the liver exhibited no significant increases in either CD8+ T cells or dendritic cells after treatment. CD40 cells on hematopoietic cells are the primary target for anti-CD40 and IL-2 therapy. The results also suggest that the immunologic events in the liver may be more revealing that those in lymphoid organs with regard to critical events related to responses after therapy.

Original languageEnglish (US)
Pages (from-to)534-539
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Interleukin-2
Neoplasms
Liver
Dendritic Cells
Spleen
T-Lymphocytes
Renal Cell Carcinoma
Transplantation Chimera
Therapeutics
Bone Marrow
Bone Marrow Transplantation
Endothelial Cells
Cell Count
Monoclonal Antibodies

Keywords

  • Bone marrow chimera
  • CD8 T cell
  • Dendritic cell

ASJC Scopus subject areas

  • Transplantation

Cite this

Tumor regression by anti-CD40 and interleukin-2 : Role of CD40 in hematopoietic cells and organ-specific effects. / Welniak, Lisbeth A.; Shorts, Lynnette; Subleski, Jeff; Blazar, Bruce R.; Wiltrout, Robert H.; Murphy, William J.

In: Biology of Blood and Marrow Transplantation, Vol. 10, No. 8, 08.2004, p. 534-539.

Research output: Contribution to journalArticle

Welniak, Lisbeth A. ; Shorts, Lynnette ; Subleski, Jeff ; Blazar, Bruce R. ; Wiltrout, Robert H. ; Murphy, William J. / Tumor regression by anti-CD40 and interleukin-2 : Role of CD40 in hematopoietic cells and organ-specific effects. In: Biology of Blood and Marrow Transplantation. 2004 ; Vol. 10, No. 8. pp. 534-539.
@article{8032f579ede84c8da55d3d9f433dff28,
title = "Tumor regression by anti-CD40 and interleukin-2: Role of CD40 in hematopoietic cells and organ-specific effects",
abstract = "CD40 stimulation can synergize with interleukin (IL)-2 for antitumor responses against mouse metastatic renal cell carcinomas, with coincident increases in tumor-specific CD8+ T-cell responses and dendritic cell numbers in both the spleen and liver. Because CD40 is present on various hematopoietic-derived cells, endothelial cells, and some tumors themselves, this study was performed to determine whether the antitumor effects of CD40 stimulation and IL-2 were primarily mediated by CD40+ hematopoietic-derived cells. Bone marrow chimeras were created by reconstituting lethally irradiated CD40+/+ recipients with bone marrow from CD40-/- or CD40+/+ mice. Chimeric mice were then implanted orthotopically with renal cancer cells, followed by treatment with anti-CD40 agonist monoclonal antibodies and IL-2. Immune parameters of the spleen and liver were assessed after therapy and correlated with antitumor responses. The antitumor effects in the CD40-/- bone marrow transplantation chimeras were almost completely abrogated after treatment, and this shows that hematopoietically derived CD40+ cells are the principal targets for CD40 stimulation in this model. Although both spleen and liver showed reductions in CD8+ T-cell and dendritic cell expansion in the CD40-/- versus CD40+/+ chimeras after therapy, only the liver exhibited no significant increases in either CD8+ T cells or dendritic cells after treatment. CD40 cells on hematopoietic cells are the primary target for anti-CD40 and IL-2 therapy. The results also suggest that the immunologic events in the liver may be more revealing that those in lymphoid organs with regard to critical events related to responses after therapy.",
keywords = "Bone marrow chimera, CD8 T cell, Dendritic cell",
author = "Welniak, {Lisbeth A.} and Lynnette Shorts and Jeff Subleski and Blazar, {Bruce R.} and Wiltrout, {Robert H.} and Murphy, {William J}",
year = "2004",
month = "8",
doi = "10.1016/j.bbmt.2004.05.006",
language = "English (US)",
volume = "10",
pages = "534--539",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Tumor regression by anti-CD40 and interleukin-2

T2 - Role of CD40 in hematopoietic cells and organ-specific effects

AU - Welniak, Lisbeth A.

AU - Shorts, Lynnette

AU - Subleski, Jeff

AU - Blazar, Bruce R.

AU - Wiltrout, Robert H.

AU - Murphy, William J

PY - 2004/8

Y1 - 2004/8

N2 - CD40 stimulation can synergize with interleukin (IL)-2 for antitumor responses against mouse metastatic renal cell carcinomas, with coincident increases in tumor-specific CD8+ T-cell responses and dendritic cell numbers in both the spleen and liver. Because CD40 is present on various hematopoietic-derived cells, endothelial cells, and some tumors themselves, this study was performed to determine whether the antitumor effects of CD40 stimulation and IL-2 were primarily mediated by CD40+ hematopoietic-derived cells. Bone marrow chimeras were created by reconstituting lethally irradiated CD40+/+ recipients with bone marrow from CD40-/- or CD40+/+ mice. Chimeric mice were then implanted orthotopically with renal cancer cells, followed by treatment with anti-CD40 agonist monoclonal antibodies and IL-2. Immune parameters of the spleen and liver were assessed after therapy and correlated with antitumor responses. The antitumor effects in the CD40-/- bone marrow transplantation chimeras were almost completely abrogated after treatment, and this shows that hematopoietically derived CD40+ cells are the principal targets for CD40 stimulation in this model. Although both spleen and liver showed reductions in CD8+ T-cell and dendritic cell expansion in the CD40-/- versus CD40+/+ chimeras after therapy, only the liver exhibited no significant increases in either CD8+ T cells or dendritic cells after treatment. CD40 cells on hematopoietic cells are the primary target for anti-CD40 and IL-2 therapy. The results also suggest that the immunologic events in the liver may be more revealing that those in lymphoid organs with regard to critical events related to responses after therapy.

AB - CD40 stimulation can synergize with interleukin (IL)-2 for antitumor responses against mouse metastatic renal cell carcinomas, with coincident increases in tumor-specific CD8+ T-cell responses and dendritic cell numbers in both the spleen and liver. Because CD40 is present on various hematopoietic-derived cells, endothelial cells, and some tumors themselves, this study was performed to determine whether the antitumor effects of CD40 stimulation and IL-2 were primarily mediated by CD40+ hematopoietic-derived cells. Bone marrow chimeras were created by reconstituting lethally irradiated CD40+/+ recipients with bone marrow from CD40-/- or CD40+/+ mice. Chimeric mice were then implanted orthotopically with renal cancer cells, followed by treatment with anti-CD40 agonist monoclonal antibodies and IL-2. Immune parameters of the spleen and liver were assessed after therapy and correlated with antitumor responses. The antitumor effects in the CD40-/- bone marrow transplantation chimeras were almost completely abrogated after treatment, and this shows that hematopoietically derived CD40+ cells are the principal targets for CD40 stimulation in this model. Although both spleen and liver showed reductions in CD8+ T-cell and dendritic cell expansion in the CD40-/- versus CD40+/+ chimeras after therapy, only the liver exhibited no significant increases in either CD8+ T cells or dendritic cells after treatment. CD40 cells on hematopoietic cells are the primary target for anti-CD40 and IL-2 therapy. The results also suggest that the immunologic events in the liver may be more revealing that those in lymphoid organs with regard to critical events related to responses after therapy.

KW - Bone marrow chimera

KW - CD8 T cell

KW - Dendritic cell

UR - http://www.scopus.com/inward/record.url?scp=3543122350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543122350&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2004.05.006

DO - 10.1016/j.bbmt.2004.05.006

M3 - Article

C2 - 15282531

AN - SCOPUS:3543122350

VL - 10

SP - 534

EP - 539

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -